SkinBioTherapeutics (SBTX) AI Stock Analysis

• Market Cap: £34.29M
• Dividend Yield: N/A
• Average Volume (3M): 673.17K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.72
• Revenue Growth: 283.74%
• EPS Growth: 78.57%
• Country: UK
• Employees: 15
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): <0.01
• Shares Outstanding: 258,779,450
• 10 Day Avg. Volume: 831,404
• 30 Day Avg. Volume: 673,172
• PEG Ratio: 0.00
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 40 Underperform
• Price Target: 16.00p ▲(20.75% Upside)

The overall stock score is primarily impacted by the company's financial performance challenges, including unprofitability and negative cash flows. Technical analysis indicates bearish momentum, and valuation concerns are heightened by a negative P/E ratio and lack of dividend yield. These factors collectively suggest caution for potential investors.

Positive Factors

Revenue Growth

Strong revenue growth indicates expanding market reach and product adoption, supporting long-term business viability and potential profitability.

Market Position

By leveraging proprietary technology in a niche market, SBTX strengthens its competitive position, potentially leading to sustained growth and market leadership.

Balance Sheet Health

A strong balance sheet with low leverage provides financial stability and flexibility, enabling SBTX to invest in growth opportunities and weather economic fluctuations.

Negative Factors

Profitability Challenges

Ongoing unprofitability and negative margins highlight operational challenges, which could hinder long-term sustainability and require strategic cost management.

Cash Flow Issues

Negative cash flows indicate potential liquidity issues, limiting the company's ability to fund operations and invest in growth without external financing.

Operational Efficiency

Improving operational efficiency is crucial for SBTX to achieve sustainable growth and profitability, impacting its ability to compete effectively in the market.

SkinBioTherapeutics Business Overview & Revenue Model

Company Description

SkinBioTherapeutics (SBTX) is a biotechnology company focused on developing innovative skincare products that harness the power of the skin microbiome. Operating in the health and beauty sector, SBTX aims to create products that not only enhance skin health but also address various dermatological issues. The company's core offerings include topical formulations designed to support skin barrier function and promote overall skin wellness, utilizing proprietary technology to extract and apply beneficial bacteria-derived ingredients.

How the Company Makes Money

SkinBioTherapeutics generates revenue primarily through the sale of its skincare products, which are marketed to both consumers and healthcare professionals. The company may leverage partnerships with established cosmetics and dermatology brands to distribute its products more effectively, creating additional revenue streams through licensing agreements or co-branding initiatives. Furthermore, SBTX may engage in research collaborations and clinical trials, potentially earning income through grants or funding from institutions interested in the therapeutic applications of its microbiome-based solutions. The company's focus on scientific validation and efficacy can also enhance marketability, thereby contributing to its earnings growth.

SkinBioTherapeutics Financial Statement Overview

Summary

SkinBioTherapeutics has shown revenue growth but continues to face significant financial challenges. The company reported substantial net losses and negative cash flows. Despite low debt levels, declining equity and unsustainable financing activities pose risks to financial stability.

Income Statement

The company has shown significant revenue growth, increasing from zero in previous years to £1.2 million in 2024. However, the gross profit margin stands at 56.5%, indicating some level of cost control. Despite this, the net profit margin is negative due to high operating expenses, resulting in a substantial net loss. EBIT and EBITDA margins are also negative, reflecting ongoing operational challenges.

Balance Sheet

The balance sheet presents a mixed picture. The debt-to-equity ratio is low at 0.28, indicating limited leverage. However, stockholders' equity has been decreasing over recent years, which is concerning. The equity ratio is 56.9%, suggesting moderate reliance on equity financing. Overall, the company's financial stability shows risk due to declining equity.

Cash Flow

Operating cash flow remains negative, though financing activities have provided cash inflows. The free cash flow is negative, indicating cash burn. The operating cash flow to net income ratio is around 0.95, showing that operational cash flows are still insufficient to cover losses. The company's cash position has been bolstered by financing activities, which is unsustainable long-term.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	4.64M	4.64M	1.21M	132.06K	74.76K	0.00
Gross Profit	2.71M	2.71M	683.04K	85.19K	45.34K	-5.05K
EBITDA	-223.19K	-196.54K	-2.72M	-2.96M	-2.95M	-1.49M
Net Income	-696.15K	-696.25K	-2.88M	-2.84M	-2.79M	-1.43M
Balance Sheet
Total Assets	12.13M	12.13M	5.22M	2.59M	3.08M	5.73M
Cash, Cash Equivalents and Short-Term Investments	4.78M	4.78M	800.90K	1.31M	1.80M	4.61M
Total Debt	993.47K	993.47K	818.74K	100.65K	127.86K	139.85K
Total Liabilities	2.71M	2.71M	2.25M	599.34K	609.61K	519.67K
Stockholders Equity	9.42M	9.42M	2.97M	1.99M	2.48M	5.22M
Cash Flow
Free Cash Flow	-1.30M	-1.30M	-2.92M	-2.81M	-2.77M	-1.67M
Operating Cash Flow	-1.30M	-1.30M	-2.73M	-2.65M	-2.67M	-1.56M
Investing Cash Flow	-1.62M	-1.62M	-2.30M	-165.28K	-96.81K	-112.31K
Financing Cash Flow	6.90M	6.90M	4.51M	2.32M	-35.12K	4.12M

SkinBioTherapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 13.25
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:SBTX, the sentiment is Negative. The current price of 13.25 is below the 20-day moving average (MA) of 14.75, below the 50-day MA of 15.29, and below the 200-day MA of 17.55, indicating a bearish trend. The MACD of -0.73 indicates Positive momentum. The RSI at 35.75 is Neutral, neither overbought nor oversold. The STOCH value of 44.12 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:SBTX.

SkinBioTherapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TRX	49 Neutral	£5.16M	-4.90	-5.41%	―	-20.31%	-19.35%
SAR	47 Neutral	£22.44M	-4.82	-202.14%	―	―	23.76%
SBTX	40 Underperform	£34.29M	-40.15	-11.24%	―	283.74%	78.57%
OBI	37 Underperform	£49.89M	-2.42	―	―	63.25%	8.94%

SkinBioTherapeutics Corporate Events

SkinBioTherapeutics Secures UK Distribution Deal with Superdrug

SkinBioTherapeutics has announced an exclusive UK commercial agreement with Superdrug Stores plc for its AxisBiotix™ food supplements, aimed at alleviating inflammatory skin conditions. This partnership is expected to enhance the company’s market presence and distribution capabilities in the UK, potentially benefiting stakeholders by expanding the reach of its innovative skin health solutions.

David Brierwood Increases Stake in SkinBioTherapeutics

David Campbell Brierwood has increased his voting rights in SkinBioTherapeutics PLC to 6.34%, up from a previous position of 5.561%. This acquisition of voting rights signifies a notable shift in shareholder influence, potentially impacting the company’s strategic decisions and stakeholder dynamics.

SkinBioTherapeutics Raises £4.2 Million Through Share Issuance

SkinBioTherapeutics plc has successfully raised approximately £4.2 million through a combination of a Placing, Subscription, and WRAP Retail Offer, issuing a total of 24,704,836 new Ordinary Shares at 17 pence per share. This capital raise will support the company’s operational and strategic initiatives, with the new shares expected to be admitted to trading on AIM by 24 June 2025, thereby increasing the company’s total voting rights and share capital.

SkinBioTherapeutics Launches £0.62m Retail Offer Amid Broader Fundraising Efforts

SkinBioTherapeutics plc has announced a retail offer through the Winterflood Retail Access Platform to raise up to £0.62 million by issuing new ordinary shares. This offer is part of a broader fundraising effort, including a placing and subscription to raise approximately £4.1 million. The initiative aims to strengthen the company’s financial position and expand its operations, with the new shares expected to commence trading on AIM on June 24, 2025. This move underscores the company’s commitment to its retail shareholder base and its strategic growth in the skin health sector.

SkinBioTherapeutics Secures Superdrug Deal and Raises £4.1m

SkinBioTherapeutics has signed an exclusive UK commercial agreement with Superdrug for its AxisBiotix™ products, marking a significant milestone as it enters the national high street market. To support this agreement and future product development, the company has raised £4.1 million through a placing and subscription, with an additional proposed retail offer to existing shareholders. The AxisBiotix-Ps product has also received the US National Psoriasis Foundation’s Seal of Recognition, enhancing its credibility and market potential in the USA.

SkinBioTherapeutics Appoints New Adviser and Broker

SkinBioTherapeutics plc has appointed Singer Capital Markets as its Nominated Adviser and Sole Broker, effective immediately. This strategic move is expected to enhance the company’s operational capabilities and market positioning, potentially benefiting stakeholders through improved advisory and brokerage services.

SkinBioTherapeutics Announces Change in Major Holdings

SkinBioTherapeutics PLC, a company involved in the biotechnology sector, has announced a change in its major holdings. The University of Manchester has reduced its voting rights in the company from 3.42% to 2.93%, as of April 29, 2025. This reduction in voting rights could impact the company’s shareholder dynamics and influence future decisions.

SkinBioTherapeutics Announces Change in Voting Rights Structure

SkinBioTherapeutics PLC has announced a change in the breakdown of its voting rights, with Optibiotix Health plc now holding 7.95% of the voting rights, down from a previous 8.46%. This adjustment in voting rights reflects a shift in stakeholder influence within the company, potentially impacting its strategic decisions and governance.